Big gains don't have to come from low-price stocks.
News & Analysis: Invitae
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
Earnings and a proposed equity raise have these stocks making after-hours moves.
The genetic-testing leader is trading at multiyear highs on the heels of impressive growth in 2018, but it still isn't profitable.
NVTA earnings call for the period ending December 31, 2018.
The group rebounded after a terrible end to 2018, but each has big plans for the year ahead.
Do these under-the-radar stocks deserve a spot in your growth stock portfolio?
This underfollowed pipeline operator, genetic testing company, and gaming stock could score big wins for their investors well before Wall Street takes notice.
The genetic-testing leader announced preliminary full-year 2018 operating results.
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.